Exciting News from Viking Therapeutics! VK2809 Shows Promise in Phase 2b Clinical Trial Oral Late Breaker Presentation Summarizes Positive Results Recently, Viking Therapeutics, Inc. announced final results from their Phase 2b clinical trial of VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with NASH (non-alcoholic steatohepatitis). The data presented at the 75th Liver…

Demo to Highlight Spectra7’s GC1122 and Keysight’s AresONE-M 800GE Layer 1-3 Test System Introduction Atlanta, Nov. 19, 2024 – Spectra7 Microsystems Inc. (“Spectra7” or the “Company”) and Keysight, a leading provider of electronic design, test, security, and software solutions, have announced their collaboration to demonstrate robust performance testing of 800Gbps Active Copper Interconnects (ACCs) at…

Exciting Developments in Psychedelic Medicine: Tryptamine Therapeutics Advances to Phase 2 Clinical Trials The Breakthrough Study The recently completed Phase 1b study of Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) has created quite a buzz in the medical community. This innovative study successfully met all key objectives, paving the way for the advancement to Phase 2 clinical…

Oh No! Domino’s Pizza Facing Class Action Lawsuit Well folks, it looks like our favorite go-to for late-night cravings, Domino’s Pizza, is in hot water. Pomerantz LLP has announced a class action lawsuit against the beloved pizza chain and some of its top officers. The lawsuit, filed in the United States District Court for the…

FinVolution Group Announces Strong Third Quarter Financial Results Overview SHANGHAI, Nov. 18, 2024 /PRNewswire/ — FinVolution Group (“FinVolution” or the “Company”) (NYSE: FINV) has reported positive financial results for the third quarter ended September 30, 2024. The company’s total transaction volume reached RMB52.2 billion, representing a 1.8% year-over-year increase. Additionally, the international transaction volume saw…